Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Mendelian Genomics, |
RCV000626682 | SCV000747385 | likely pathogenic | Telecanthus; Hyperextensible skin; Joint hypermobility; Neuropathic spinal arthropathy | 2017-01-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002233904 | SCV001392839 | likely pathogenic | Ehlers-Danlos syndrome, classic type, 1 | 2019-07-03 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed to be de novo in an individual with clinical features of connective tissue disease (Invitae). ClinVar contains an entry for this variant (Variation ID: 523366). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with cysteine at codon 252 of the COL5A2 protein (p.Gly252Cys). The glycine residue is highly conserved and there is a large physicochemical difference between glycine and cysteine. |
Fulgent Genetics, |
RCV002491344 | SCV002775263 | likely pathogenic | Ehlers-Danlos syndrome, classic type, 2 | 2022-05-28 | criteria provided, single submitter | clinical testing |